Clinical report: Crinetics ready to advance oral acromegaly therapy to FDA

It was a week of both milestones and setbacks in the development of endocrine disease therapies, with Phase III data for a once-daily oral acromegaly therapy from Crinetics Inc. (NASDAQ:CRNX) keeping the company’s NDA submission on track, and Phase II congenital adrenal hyperplasia results from Spruce Biosciences Inc. (NASDAQ:SPRB) leading to a workforce reduction and trial discontinuation.

Shares of Crinetics gained 19% to $45.18 on Tuesday, translating to a market cap gain of over $500 million, after the company reported that its lead candidate met the primary endpoint in a second Phase III acromegaly study, keeping it on schedule for an NDA submission next half. ...